Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.
Regulation
The need for amendments to the Patented Medicines (Notice of Compliance) Regulations of the Patent Act and address operational concerns: bring finality to proceedings under the Regulations, allow generic manufacturers to amend a Notice of Allegation (NOA), and provide meaningful damages and other disincentives to discourage abuse of the Regulations by brand-name companies.